{"id":8156,"date":"2026-05-15T06:24:30","date_gmt":"2026-05-14T22:24:30","guid":{"rendered":"http:\/\/longzhuplatform.com\/?p=8156"},"modified":"2026-05-15T06:24:30","modified_gmt":"2026-05-14T22:24:30","slug":"%e0%a4%ae%e0%a4%9c%e0%a4%ac%e0%a5%82%e0%a4%a4-q4-%e0%a4%a8%e0%a4%a4%e0%a5%80%e0%a4%9c%e0%a5%8b%e0%a4%82-%e0%a4%95%e0%a5%87-%e0%a4%ac%e0%a4%be%e0%a4%a6-%e0%a4%87%e0%a4%b8-%e0%a4%ab%e0%a4%be%e0%a4%b0","status":"publish","type":"post","link":"http:\/\/longzhuplatform.com\/?p=8156","title":{"rendered":"\u092e\u091c\u092c\u0942\u0924 Q4 \u0928\u0924\u0940\u091c\u094b\u0902 \u0915\u0947 \u092c\u093e\u0926 \u0907\u0938 \u092b\u093e\u0930\u094d\u092e\u093e \u0936\u0947\u092f\u0930 \u092e\u0947\u0902 \u0906\u0908 \u091c\u094b\u0930\u0926\u093e\u0930 \u0924\u0947\u091c\u0940! 6 \u092a\u094d\u0930\u0924\u093f\u0936\u0924 \u0938\u0947 \u091c\u094d\u092f\u093e\u0926\u093e \u0909\u091b\u0932\u093e \u0936\u0947\u092f\u0930-  \u092a\u094d\u0930\u0949\u092b\u093f\u091f 91% \u0909\u091b\u0932\u093e"},"content":{"rendered":"<p><\/p> <div> <p><strong>Stock in Focus: <\/strong>\u0936\u0947\u092f\u0930 \u092c\u093e\u091c\u093e\u0930 \u092e\u0947\u0902 \u092c\u0941\u0927\u0935\u093e\u0930 \u0915\u094b\u00a0\u0930\u093f\u0915\u0935\u0930\u0940 \u0926\u0947\u0916\u0928\u0947 \u0915\u094b \u092e\u093f\u0932 \u0930\u0939\u0940 \u0939\u0948\u0964 \u0938\u0941\u092c\u0939 \u0915\u0940 \u0917\u093f\u0930\u093e\u0935\u091f \u0915\u0947 \u092c\u093e\u0926 \u0926\u094b\u092a\u0939\u0930 12 \u092c\u091c\u0947 \u0924\u0915 \u0938\u0947\u0902\u0938\u0947\u0915\u094d\u0938 \u0914\u0930 \u0928\u093f\u092b\u094d\u091f\u0940 \u0939\u0930\u0947 \u0928\u093f\u0936\u093e\u0928 \u092a\u0930 \u091f\u094d\u0930\u0947\u0921 \u0915\u0930 \u0930\u0939\u093e \u0939\u0948\u0964 \u0907\u0938 \u0924\u0947\u091c\u0940 \u0915\u0947 \u092c\u0940\u091a \u0930\u0921\u093e\u0930 \u092a\u0930 \u092b\u093e\u0930\u094d\u092e\u093e \u0938\u0947\u0915\u094d\u091f\u0930 \u0915\u0940 \u0915\u0902\u092a\u0928\u0940- \u0938\u093e\u0915\u093e\u0930 \u0939\u0947\u0932\u094d\u0925\u0915\u0947\u092f\u0930 \u0932\u093f\u092e\u093f\u091f\u0947\u0921 (Sakar Healthcare Limited) \u0939\u0948\u0964<\/p> <div class=\"related_article\"> <h4 class=\"ra_heading\">\u0938\u092e\u094d\u092c\u0902\u0927\u093f\u0924 \u0916\u093c\u092c\u0930\u0947\u0902<\/h4> <\/div> <p>\u0926\u094b\u092a\u0939\u0930 12:06 \u092c\u091c\u0947 \u0924\u0915 \u0936\u0947\u092f\u0930 \u090f\u0928\u090f\u0938\u0908 \u092a\u0930 6.64% \u092f\u093e 37.85 \u0930\u0941\u092a\u092f\u0947 \u091a\u0922\u093c\u0915\u0930\u00a0607.50 \u0930\u0941\u092a\u092f\u0947 \u092a\u0930 \u091f\u094d\u0930\u0947\u0921 \u0915\u0930 \u0930\u0939\u093e \u0925\u093e\u0964 \u0936\u0947\u092f\u0930 \u092e\u0947\u0902 \u0924\u0947\u091c\u0940 \u0915\u0947 \u092a\u0940\u091b\u0947 \u0915\u0902\u092a\u0928\u0940 \u0926\u094d\u0935\u093e\u0930\u093e \u091c\u093e\u0930\u0940 \u0915\u093f\u090f \u0917\u090f \u092e\u091c\u092c\u0942\u0924 \u0924\u093f\u092e\u093e\u0939\u0940 \u0928\u0924\u0940\u091c\u0947 \u0939\u0948\u0902\u0964<\/p> <p>Q4FY26 \u0914\u0930 \u092a\u0942\u0930\u0947 FY26 \u0915\u093e \u0915\u0902\u0938\u094b\u0932\u093f\u0921\u0947\u091f \u0928\u092c\u0902\u0930\u094d\u0938 \u092c\u0924\u093e\u0924\u0947 \u0939\u0941\u090f \u0915\u0902\u092a\u0928\u0940 \u0928\u0947 \u092c\u0924\u093e\u092f\u093e \u0915\u093f\u00a0Q4FY26 \u092e\u0947\u0902 \u0915\u0902\u092a\u0928\u0940 \u0915\u0940 \u0911\u092a\u0930\u0947\u0936\u0902\u0938 \u0938\u0947 \u0906\u092f \u092c\u0922\u093c\u0915\u0930 71.09 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0930\u0939\u0940, \u091c\u094b Q4FY25 \u092e\u0947\u0902 50.24 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0925\u0940\u0964 \u092f\u093e\u0928\u0940 \u0938\u093e\u0932\u093e\u0928\u093e \u0906\u0927\u093e\u0930 \u092a\u0930 42% \u0915\u0940 \u092c\u0922\u093c\u094b\u0924\u0930\u0940 \u0939\u0941\u0908\u0964 \u0935\u0939\u0940\u0902 \u0917\u094d\u0930\u0949\u0938 \u092a\u094d\u0930\u0949\u092b\u093f\u091f 20% \u092c\u0922\u093c\u0915\u0930 42.71 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u092a\u0939\u0941\u0902\u091a \u0917\u092f\u093e\u0964 \u0939\u093e\u0932\u093e\u0902\u0915\u093f \u0917\u094d\u0930\u0949\u0938 \u092a\u094d\u0930\u0949\u092b\u093f\u091f \u092e\u093e\u0930\u094d\u091c\u093f\u0928 \u0918\u091f\u0915\u0930 60% \u0930\u0939 \u0917\u092f\u093e, \u091c\u094b \u092a\u093f\u091b\u0932\u0947 \u0938\u093e\u0932 71% \u0925\u093e\u0964<\/p> <p>\u0915\u0902\u092a\u0928\u0940 \u0915\u093e EBITDA Q4FY26 \u092e\u0947\u0902 67% \u092c\u0922\u093c\u0915\u0930 26.23 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0930\u0939\u093e, \u091c\u092c\u0915\u093f EBITDA \u092e\u093e\u0930\u094d\u091c\u093f\u0928 31% \u0938\u0947 \u092c\u0922\u093c\u0915\u0930 37% \u0939\u094b \u0917\u092f\u093e\u0964 \u0935\u0939\u0940\u0902 \u0915\u0902\u092a\u0928\u0940 \u0915\u093e \u092a\u094d\u0930\u0949\u092b\u093f\u091f \u0906\u092b\u094d\u091f\u0930 \u091f\u0948\u0915\u094d\u0938 (PAT) 91% \u0915\u0940 \u091c\u094b\u0930\u0926\u093e\u0930 \u092c\u0922\u093c\u0924 \u0915\u0947 \u0938\u093e\u0925 11.02 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u092a\u0939\u0941\u0902\u091a \u0917\u092f\u093e\u0964 PAT \u092e\u093e\u0930\u094d\u091c\u093f\u0928 \u092d\u0940 11% \u0938\u0947 \u092c\u0922\u093c\u0915\u0930 16% \u0939\u094b \u0917\u092f\u093e\u0964<\/p> <p>\u092a\u0942\u0930\u0947 \u0935\u093f\u0924\u094d\u0924 \u0935\u0930\u094d\u0937 FY26 \u0915\u0940 \u092c\u093e\u0924 \u0915\u0930\u0947\u0902 \u0924\u094b \u0915\u0902\u092a\u0928\u0940 \u0915\u0940 \u0915\u0941\u0932 \u0906\u092f 42% \u092c\u0922\u093c\u0915\u0930 251.73 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0930\u0939\u0940, \u091c\u094b FY25 \u092e\u0947\u0902 177.58 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0925\u0940\u0964 \u0917\u094d\u0930\u0949\u0938 \u092a\u094d\u0930\u0949\u092b\u093f\u091f 35% \u092c\u0922\u093c\u0915\u0930 128.45 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u092a\u0939\u0941\u0902\u091a \u0917\u092f\u093e\u0964 EBITDA 39% \u092c\u0922\u093c\u0915\u0930 68.88 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0930\u0939\u093e, \u091c\u092c\u0915\u093f \u0915\u0902\u092a\u0928\u0940 \u0915\u093e \u092e\u0941\u0928\u093e\u092b\u093e 74% \u092c\u0922\u093c\u0915\u0930 30.48 \u0915\u0930\u094b\u0921\u093c \u0930\u0941\u092a\u092f\u0947 \u0939\u094b \u0917\u092f\u093e\u0964 FY26 \u092e\u0947\u0902 PAT \u092e\u093e\u0930\u094d\u091c\u093f\u0928 10% \u0938\u0947 \u092c\u0922\u093c\u0915\u0930 12% \u0939\u094b \u0917\u092f\u093e\u0964<\/p> <p><strong>\u092c\u093f\u091c\u0928\u0947\u0938 \u0905\u092a\u0921\u0947\u091f<\/strong><\/p> <p>\u0915\u0902\u092a\u0928\u0940 \u0928\u0947 \u092c\u0924\u093e\u092f\u093e \u0915\u093f Q4 \u0914\u0930 FY26 \u0915\u0947 \u0926\u094c\u0930\u093e\u0928\u00a0\u0915\u0902\u092a\u0928\u0940 \u0928\u0947 \u0911\u0928\u094d\u0915\u094b\u0932\u0949\u091c\u0940 (\u0915\u0948\u0902\u0938\u0930) \u0938\u0947 \u091c\u0941\u0921\u093c\u0947 60 \u0938\u0947 \u091c\u094d\u092f\u093e\u0926\u093e \u092c\u093f\u091c\u0928\u0947\u0938 \u0915\u0949\u0928\u094d\u091f\u094d\u0930\u0948\u0915\u094d\u091f \u092a\u0942\u0930\u0947 \u0915\u093f\u090f, \u091c\u092c\u0915\u093f 35 \u0938\u0947 \u0905\u0927\u093f\u0915 \u0921\u0940\u0932\u094d\u0938 \u092a\u0930 \u0905\u092d\u0940 \u092c\u093e\u0924\u091a\u0940\u0924 \u091c\u093e\u0930\u0940 \u0939\u0948\u0964 \u0915\u0902\u092a\u0928\u0940 \u0928\u0947 \u0926\u0941\u0928\u093f\u092f\u093e\u092d\u0930 \u092e\u0947\u0902 250 \u0921\u094b\u091c\u093f\u092f\u0930 \u0936\u0947\u092f\u0930 \u0915\u093f\u090f \u0939\u0948\u0902, \u091c\u093f\u0928\u092e\u0947\u0902 \u0938\u0947 125 \u091c\u092e\u093e \u0915\u093f\u090f \u091c\u093e \u091a\u0941\u0915\u0947 \u0939\u0948\u0902 \u0914\u0930 12 \u0915\u094b \u0930\u0947\u0917\u0941\u0932\u0947\u091f\u0930\u0940 \u0905\u0925\u0949\u0930\u093f\u091f\u0940\u091c \u0938\u0947 \u092e\u093e\u0930\u094d\u0915\u0947\u091f\u093f\u0902\u0917 \u0905\u092a\u094d\u0930\u0942\u0935\u0932 \u092e\u093f\u0932 \u091a\u0941\u0915\u093e \u0939\u0948\u0964<\/p> <p>\u0915\u0902\u092a\u0928\u0940 \u0926\u094d\u0935\u093e\u0930\u093e \u0935\u093f\u0915\u0938\u093f\u0924 32 \u0911\u0928\u094d\u0915\u094b\u0932\u0949\u091c\u0940 \u092a\u094d\u0930\u094b\u0921\u0915\u094d\u091f\u094d\u0938 \u092e\u0947\u0902 \u0938\u0947 21 \u0915\u0947 \u0921\u094b\u091c\u093f\u092f\u0930 \u0936\u0947\u092f\u0930 \u0915\u093f\u090f \u0917\u090f, \u091c\u093f\u0928\u092e\u0947\u0902 11 \u0921\u094b\u091c\u093f\u092f\u0930 \u0915\u094b \u092e\u0902\u091c\u0942\u0930\u0940 \u092e\u093f\u0932 \u091a\u0941\u0915\u0940 \u0939\u0948\u0964 \u0907\u0928\u092e\u0947\u0902 Abiraterone, Imatinib, Tamoxifen, Capecitabine, Gemcitabine, Carboplatin, Irinotecan \u0914\u0930 Docetaxel \u091c\u0948\u0938\u0947 \u0915\u0948\u0902\u0938\u0930 \u0926\u0935\u093e\u0913\u0902 \u0915\u0947 \u092a\u094d\u0930\u094b\u0921\u0915\u094d\u091f \u0936\u093e\u092e\u093f\u0932 \u0939\u0948\u0902\u0964<\/p> <p>\u0907\u0938\u0915\u0947 \u0905\u0932\u093e\u0935\u093e \u0915\u0902\u092a\u0928\u0940 \u0915\u0947 \u091f\u0947\u0915\u094d\u0928\u094b\u0932\u0949\u091c\u0940 \u091f\u094d\u0930\u093e\u0902\u0938\u092b\u0930 \u092a\u094d\u0930\u094b\u091c\u0947\u0915\u094d\u091f\u094d\u0938 Accord-Intas, Torrent UK &amp; Germany, Emcure, Glenmark \u0914\u0930 Zydus \u091c\u0948\u0938\u0940 \u0915\u0902\u092a\u0928\u093f\u092f\u094b\u0902 \u0915\u0947 \u0938\u093e\u0925 \u091c\u093e\u0930\u0940 \u0939\u0948\u0902\u0964 \u0907\u0928\u092e\u0947\u0902 \u0938\u0947 4 \u092a\u094d\u0930\u094b\u091c\u0947\u0915\u094d\u091f\u094d\u0938 \u0915\u094b \u0938\u093e\u0907\u091f \u0935\u0947\u0930\u093f\u090f\u0936\u0928 \u0905\u092a\u094d\u0930\u0942\u0935\u0932 \u092d\u0940 \u092e\u093f\u0932 \u091a\u0941\u0915\u093e \u0939\u0948, \u091c\u093f\u0928\u092e\u0947\u0902 2 UK \u0914\u0930 2 \u092f\u0942\u0930\u094b\u092a\u093f\u092f\u0928 \u092f\u0942\u0928\u093f\u092f\u0928 (EU) \u0938\u0947 \u0939\u0948\u0902\u0964<\/p> <\/div> <p>Sakar Healthcare share price, Sakar Healthcare Q4FY26 results, pharma stock rally today, oncology pharma company india, Sakar Healthcare profit growth, Sakar Healthcare EBITDA growth, pharma stocks in focus, small cap pharma stocks india, cancer drug company india, oncology products approvals, Sakar Healthcare latest news, NSE pharma shares, pharma company quarterly results, stock market news india, pharma sector stocks today, Sakar Healthcare FY26 performance, oncology business contracts, pharma export company india, cancer medicine manufacturing india, pharmaceutical company earnings, indian pharma stocks rally, healthcare stocks india, multibagger pharma stocks, Sakar Healthcare PAT growth, oncology dossier approvals, indian stock market updates, pharma company global expansion, Accord Intas technology transfer, Glenmark Zydus oncology projects, pharma industry news india#\u092e\u091c\u092c\u0924 #\u0928\u0924\u091c #\u0915 #\u092c\u0926 #\u0907\u0938 #\u092b\u0930\u092e #\u0936\u092f\u0930 #\u092e #\u0906\u0908 #\u091c\u0930\u0926\u0930 #\u0924\u091c #\u092a\u0930\u0924\u0936\u0924 #\u0938 #\u091c\u092f\u0926 #\u0909\u091b\u0932 #\u0936\u092f\u0930 #\u092a\u0930\u092b\u091f #\u0909\u091b\u09321778797470<\/p> ","protected":false},"excerpt":{"rendered":"<p>Stock in Focus: \u0936\u0947\u092f\u0930 \u092c\u093e\u091c\u093e\u0930 \u092e\u0947\u0902 \u092c\u0941\u0927\u0935\u093e\u0930 \u0915\u094b\u00a0\u0930\u093f\u0915\u0935\u0930\u0940 \u0926\u0947\u0916\u0928\u0947 \u0915\u094b \u092e\u093f\u0932 \u0930\u0939\u0940 \u0939\u0948\u0964 \u0938\u0941\u092c\u0939 \u0915\u0940 \u0917\u093f\u0930\u093e\u0935\u091f \u0915\u0947 \u092c\u093e\u0926 \u0926\u094b\u092a\u0939\u0930 12 \u092c\u091c\u0947 \u0924\u0915 \u0938\u0947\u0902\u0938\u0947\u0915\u094d\u0938 \u0914\u0930 \u0928\u093f\u092b\u094d\u091f\u0940 \u0939\u0930\u0947 \u0928\u093f\u0936\u093e\u0928 \u092a\u0930 \u091f\u094d\u0930\u0947\u0921 \u0915\u0930 \u0930\u0939\u093e \u0939\u0948\u0964 \u0907\u0938 \u0924\u0947\u091c\u0940 \u0915\u0947 \u092c\u0940\u091a \u0930\u0921\u093e\u0930 \u092a\u0930 \u092b\u093e\u0930\u094d\u092e\u093e \u0938\u0947\u0915\u094d\u091f\u0930 \u0915\u0940 \u0915\u0902\u092a\u0928\u0940- \u0938\u093e\u0915\u093e\u0930 \u0939\u0947\u0932\u094d\u0925\u0915\u0947\u092f\u0930 \u0932\u093f\u092e\u093f\u091f\u0947\u0921 (Sakar Healthcare Limited) \u0939\u0948\u0964 \u0938\u092e\u094d\u092c\u0902\u0927\u093f\u0924 \u0916\u093c\u092c\u0930\u0947\u0902 \u0926\u094b\u092a\u0939\u0930 12:06 \u092c\u091c\u0947 \u0924\u0915 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[30620,30604,30613,30621,8036,30615,16835,30616,30607,30611,30618,30599,30605,30619,30608,30612,30622,30609,30598,30602,30614,30601,30610,30606,30617,30600,30597,30596,30603,1300,5069,288,2205,138,697,2590,688,5590,29931,7090,7093,293,689,3240,290,140],"class_list":["post-8156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-content-marketing","tag-accord-intas-technology-transfer","tag-cancer-drug-company-india","tag-cancer-medicine-manufacturing-india","tag-glenmark-zydus-oncology-projects","tag-healthcare-stocks-india","tag-indian-pharma-stocks-rally","tag-indian-stock-market-updates","tag-multibagger-pharma-stocks","tag-nse-pharma-shares","tag-oncology-business-contracts","tag-oncology-dossier-approvals","tag-oncology-pharma-company-india","tag-oncology-products-approvals","tag-pharma-company-global-expansion","tag-pharma-company-quarterly-results","tag-pharma-export-company-india","tag-pharma-industry-news-india","tag-pharma-sector-stocks-today","tag-pharma-stock-rally-today","tag-pharma-stocks-in-focus","tag-pharmaceutical-company-earnings","tag-sakar-healthcare-ebitda-growth","tag-sakar-healthcare-fy26-performance","tag-sakar-healthcare-latest-news","tag-sakar-healthcare-pat-growth","tag-sakar-healthcare-profit-growth","tag-sakar-healthcare-q4fy26-results","tag-sakar-healthcare-share-price","tag-small-cap-pharma-stocks-india","tag-stock-market-news-india","tag-5069","tag-288","tag-2205","tag-138","tag-697","tag-2590","tag-688","tag-5590","tag-29931","tag-7090","tag-7093","tag-293","tag-689","tag-3240","tag-290","tag-140"],"acf":[],"_links":{"self":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/8156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8156"}],"version-history":[{"count":0,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/posts\/8156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=\/wp\/v2\/media\/8157"}],"wp:attachment":[{"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8156"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/longzhuplatform.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}